HC quashes Centre's notification to ban FDC drugs

Image
IANS New Delhi
Last Updated : Dec 01 2016 | 12:02 PM IST

The Delhi High Court on Thursday quashed the Centre's notification to ban 344 fixed dose combination (FDC) medicines.

The brands included D'Cold Total, Corex cough syrup, and Vicks Action 500, among others.

Justice R.S. Endlaw, allowing the 454 pleas filed by the pharma companies, quashed the Centre's notification issued on March 10.

Companies like Pfizer, Glenmark, Procter and Gamble, Reckitt Benckiser, Cipla and others had moved the court against the government decision. The court had granted stay on the notification.

The government had told the court that FDC medicines sold by pharma majors "endanger patient safety".

It had banned the drugs on the ground that they involve risk to humans and hence needed to be withdrawn immediately and contended that safer alternatives were available.

The pharma companies had argued that the ban order was passed without considering clinical data and had termed the government's claim as absurd.

--IANS

gt/in/dg

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 01 2016 | 11:52 AM IST

Next Story